CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

计划入组 16 人 · 首次发布于 2020 年 11 月 13 日

COVID-19 SARS-CoV-2 Antibody Testing Study

计划入组 400 人 · 首次发布于 2021 年 8 月 18 日

Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB)

计划入组 200 人 · 首次发布于 2022 年 8 月 25 日

AV-103

Sotrovimab(Xevudy)

IHM-Spike

Invivyd

United States

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

Antibody Profiles Offer Insights into Long COVID Cognitive Symptoms, Study Finds

Invivyd Forms SPEAR Study Group to Investigate Monoclonal Antibody Therapy for Long COVID

Invivyd's Pemgarda Shows Continued Neutralizing Activity Against SARS-CoV-2 Variant XEC